G. Matthew Barnard: Lawyer with Duane Morris LLP

G. Matthew Barnard

Associate
Philadelphia,  PA  U.S.A.
Phone215 979 1928

Peer Rating
N/R
 N/R

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials
 

Practice Areas

  • Corporate Law
  • Private Equity
  • Mergers and Acquisitions
 
Contact InfoTelephone: 215 979 1928
Fax: 215 689 4912
http://www.duanemorris.com/attorneys/gmatthewbarnard.html
 
University The Pennsylvania State University, B.S., Finance, 2002; Temple University Fox School of Business and Management, M.B.A., 2006
 
Law SchoolTemple University Beasley School of Law, J.D., 2006
 
Admitted2006, Pennsylvania; New Jersey
 
Born1980
 
Biography

G. Matthew Barnard practices in the area of corporate law. Mr. Barnard has experience with mergers and acquisitions, private equity financings and fund offerings, as well as general corporate law.

Mr. Barnard is a 2006 graduate of Temple University Beasley School of Law. He also received an M.B.A. from Temple University, Fox School of Business and Management, and a B.S. in Finance from Pennsylvania State University.

Areas of Practice

· Corporate Law

· Mergers and Acquisitions

· Private Equity

Representative Matters

· Represented Alexar Therapeutics, Inc., a newly formed derm-focused pharmaceutical company, in connection with the sale of $21.5 million of Series A-1 and Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, venture capital firms active in the pharmaceutical space, and the simultaneous closing of the purchase of the stock of Anayaderm, a development-stage pharmaceutical company.

· Represented a major French media and sports management company in connection with the acquisition by its U.S. subsidiary of Jeff Sanders Promotions, Inc., a golf events management company based in Portland, Oregon.

· Represented Iroko Pharmaceuticals, a global specialty pharmaceutical company dedicated to advancing the science of responsible pain management, in securing $75 million in debt financing to support general business operations and the commercialization of Iroko's FDA-approved ZORVOLEX™ (diclofenac), a drug that uses iCeutica Inc.'s proprietary SoluMatrix Fine Particle Technology™ to both reduce the dosage of active ingredients ingested by the patient and accelerate the dissolution of the drug in the patient.

· Represented Ceptaris Therapeutics in its acquisition by Actelion for $250 million cash plus undisclosed milestone payments and sales earnouts.

Experience

· Duane Morris LLP
- Associate, 2011-present

· Klehr Harrison Harvey Branzburg LLP
- Associate, 2006-2011

Selected Publications

· Co-author, "Guide to Publicly Offered Private Placements Under New Rule 506(c)," Duane Morris Alert, September 26, 2013

· Co-author, "SBA Rules: Investment Funds Can Now Be Majority Owners of SBIR Companies, Duane Morris Alert, February 22, 2013; republished by VCExperts, March 13, 2013

 
Reported CasesRepresentative Matters; Represented Alexar Therapeutics, Inc., a newly formed derm-focused pharmaceutical company, in connection with the sale of $21.5 million of Series A-1 and Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, venture capital firms active in the pharmaceutical space, and the simultaneous closing of the purchase of the stock of Anayaderm, a development-stage pharmaceutical company. Represented a major French media and sports management company in connection with the acquisition by its U.S. subsidiary of Jeff Sanders Promotions, Inc., a golf events management company based in Portland, Oregon. Represented Iroko Pharmaceuticals, a global specialty pharmaceutical company dedicated to advancing the science of responsible pain management, in securing $75 million in debt financing to support general business operations and the commercialization of Iroko's FDA-approved ZORVOLEX (diclofenac), a drug that uses iCeutica Inc.'s proprietary SoluMatrix Fine Particle Technology to both reduce the dosage of active ingredients ingested by the patient and accelerate the dissolution of the drug in the patient. Represented Ceptaris Therapeutics in its acquisition by Actelion for $250 million cash plus undisclosed milestone payments and sales earnouts.
 
ISLN919048889
 
Profile Visibility
#2,022 in weekly profile views out of 15,560 lawyers in Philadelphia, Pennsylvania
#171,772 in weekly profile views out of 1,519,763 total lawyers Overall

Office Information

G. Matthew Barnard

30 South 17th Street
PhiladelphiaPA 19103-7396




Loading...
 

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now